Literature DB >> 16779512

The elevated level of circulating matrix metalloproteinase-9 in patients with abdominal aortic aneurysms decreased to levels equal to those of healthy controls after an aortic repair.

Tetsuo Watanabe1, Akira Sato, Takashi Sawai, Miwa Uzuki, Hitoshi Goto, Hiroshi Yamashita, Daijirou Akamatsu, Hiroko Sato, Takuya Shimizu, Noriyuki Miyama, Yoshiyuki Nakano, Susumu Satomi.   

Abstract

Matrix metalloproteinase-9 (MMP-9) is abundantly expressed in abdominal aortic aneurysms (AAAs), and it is considered to play a pivotal role in aneurysmal formation. Elevated circulating concentrations of MMP-9 have been reported in patients with AAA, but the influence of an operation on circulating MMP-9 is unclear. Therefore, to clarify the influence of an operation on circulating MMP-9 levels and to determine the role of MMP-9 in the progression of AAA, we measured serum MMP-9 levels in patients before and after AAA repair. Blood samples were obtained from 53 patients with AAA; 22 patients underwent AAA operations, including 17 patients with arterial occlusive disease (AOD), and nine normal control subjects. Serum MMP-9 levels were determined by an enzyme-linked immunosorbent assay. The serum MMP-9 concentration was significantly higher in AAA patients (622.0 +/- 400.2 ng/mL) than in either AOD patients (284.3 +/- 151.4 ng/mL) or healthy controls (280.8 +/- 165.5 ng/mL) (p < 0.001). The mean serum MMP-9 levels in patients undergoing surgery for AAA (268.1 +/- 215.9 ng/mL) was significantly lower than that in AAA patients (p < 0.01). Among the 10 patients whose sera were obtained preoperatively and postoperatively, the serum MMP-9 concentration fell significantly after the patients underwent the operation (p = 0.004). No significant difference was identified in serum MMP-9 concentrations among AOD patients, controls, and postoperative patients. These studies suggest that MMP-9 plays a pivotal role in aneurysm formation, and the circulating MMP-9 level is thus considered to reflect the biological behavior of the aneurysm.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16779512     DOI: 10.1007/s10016-006-9038-7

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  11 in total

1.  Circulating levels of matrix metalloproteinase-9 and abdominal aortic pathology: from the Dallas Heart Study.

Authors:  Justin L Grodin; Tiffany M Powell-Wiley; Colby R Ayers; Darpan S Kumar; Anand Rohatgi; Amit Khera; Darren K McGuire; James A de Lemos; Sandeep R Das
Journal:  Vasc Med       Date:  2011-10       Impact factor: 3.239

2.  CD95-ligand contributes to abdominal aortic aneurysm progression by modulating inflammation.

Authors:  Zhibo Liu; Matthew Fitzgerald; Trevor Meisinger; Rishi Batra; Melissa Suh; Harrison Greene; Alexander J Penrice; Lijun Sun; B Timothy Baxter; Wanfen Xiong
Journal:  Cardiovasc Res       Date:  2019-03-15       Impact factor: 10.787

Review 3.  Cysteine protease cathepsins and matrix metalloproteinases in the development of abdominal aortic aneurysms.

Authors:  Yanwen Qin; Xu Cao; Yaoguo Yang; Guo-Ping Shi
Journal:  Future Cardiol       Date:  2013-01

Review 4.  Circulating markers of abdominal aortic aneurysm presence and progression.

Authors:  Jonathan Golledge; Philip S Tsao; Ronald L Dalman; Paul E Norman
Journal:  Circulation       Date:  2008-12-02       Impact factor: 29.690

Review 5.  Role of matrix metalloproteinase inhibitors in preventing abdominal aortic aneurysm.

Authors:  Faisal Aziz; Helena Kuivaniemi
Journal:  Ann Vasc Surg       Date:  2007-05       Impact factor: 1.466

Review 6.  Abdominal Aortic Aneurysm: Evolving Controversies and Uncertainties.

Authors:  Davide Carino; Timur P Sarac; Bulat A Ziganshin; John A Elefteriades
Journal:  Int J Angiol       Date:  2018-05-29

7.  ACE inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysm.

Authors:  Kim E Kortekaas; C Arnoud Meijer; Jan Willem Hinnen; Ronald L Dalman; Baohui Xu; Jaap F Hamming; Jan H Lindeman
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

8.  Hemodynamic predictors of aortic dilatation in bicuspid aortic valve by velocity-encoded cardiovascular magnetic resonance.

Authors:  P Martijn den Reijer; Denver Sallee; Petra van der Velden; Eline R Zaaijer; W James Parks; Senthil Ramamurthy; Trevor Q Robbie; Giorgina Donati; Carey Lamphier; Rudolf P Beekman; Marijn E Brummer
Journal:  J Cardiovasc Magn Reson       Date:  2010-01-13       Impact factor: 5.364

9.  Effect of statin therapy on serum activity of proteinases and cytokines in patients with abdominal aortic aneurysm.

Authors:  Bernd Muehling; Alexander Oberhuber; Hubert Schelzig; Gisela Bischoff; Nikolaus Marx; Ludger Sunder-Plassmann; Karl H Orend
Journal:  Vasc Health Risk Manag       Date:  2008

10.  Reducing Aortic Barotrauma and Vascular Extracellular Matrix Degradation by Pacemaker-Mediated QRS Widening.

Authors:  Murat Sezer; Adem Atici; Isa Coskun; Yaşar Cizgici; Alp Ozcan; Berrin Umman; Zehra Bugra; Ilke Ozcan; Hakan Hasdemir; Mehmet Kocaaga; Justin E Davies; Sabahattin Umman
Journal:  J Am Heart Assoc       Date:  2020-05-11       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.